Search Results - brian+murphy

9 Results Sort By:
Antigenic Chimeric Tick-Borne Encephalitis Virus/Dengue Virus Type 4 Recombinant Viruses
The tick-borne encephalitis virus (TBEV) complex is a group of viruses that can cause severe neutrotropic disease and up to thirty percent (30%) mortality. While these viruses can be found in many parts of the world, the largest impact of the disease occurs in Europe and Russia, where approximately fourteen thousand (14,000) hospitalized TBEV cases...
Published: 10/28/2024   |   Inventor(s): Brian Murphy, Amber Engel, Alexander Pletnev
Keywords(s): 4, ANTIGENIC, CANDIDATES, CAUSED, chimeric, Chromosome 7, monosomy, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Deletion 7, Dengue (Flaviviridae), Development, Disease, DXXXXX, ENCEPHALITIS, Patent Category - Biotechnology, Prevention, recombinant, TBEV, TBEV/DEN4, TICK-BORNE, Tick-borne encephalitis, TYPE, Vaccine, virus, Virus/dengue, Viruses
Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease
Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation
Available for licensing and commercial development is a patent estate and related biological materials for producing therapeutic or prophylactic vaccines against Respiratory Syncytial Virus (RSV). The claimed vaccine strategy relates to the engineering and creation of live-attenuated RSV vaccine candidates by shifting the position of one or more viral...
Published: 10/28/2024   |   Inventor(s): Peter Collins, Brian Murphy, Ursula Buchholz, Stephen Whitehead, Christine Krempl
Keywords(s): ATTENUATE, Attenuated, ATTENUATING, ATTENUATION, Chromosome 7, monosomy, DC5BXX, DC5XXX, DCXXXX, Deletion 7, DXXXXX, GENES, Noonan syndrome, NS1, Promoter-proximal, RSV, RSV virus, RSV/PIV, Syncytial, Vaccine, Vaccine Design, VACCINE DEVELOPMENT, VACCINE VECTORS, vaccines, virus
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines
Neutralizing Monoclonal Antibodies to Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia among infants and children under 1 year of age. Illness begins most frequently with fever, runny nose, cough, and sometimes wheezing. During their first RSV infection, between 25% and 40% of infants and young children have signs or symptoms of bronchiolitis or...
Published: 10/28/2024   |   Inventor(s): Robert Chanock (Estate), Brian Murphy, James Crowe
Keywords(s): antibodies, DB4BXX, DB4XXX, DBXXXX, DXXXXX, monoclonal, Neutralizing, Q fever, respiratory, Syncytial, virus
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease
Development of Dengue Virus Type 3 Vaccine Candidates
The disease burden associated with dengue virus infection has increased over the past several decades in the tropical and semi-tropical regions of the world, where over 2 billion people live at risk of dengue infection. Annually, there are an estimated fifty (50) to one hundred (100) million cases of dengue fever, making development of an effective...
Published: 10/28/2024   |   Inventor(s): Joseph Blaney, Brian Murphy, Stephen Whitehead
Keywords(s): 1, 2, 3, 30, 3'-UTR, CANDIDATES, CONSISTING, Containing, Contiguous, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Deletion, DELETIONS, Delta30, DEN4, DENGUE, Dengue (Flaviviridae), DENGUE FEVER, Dervived, Development, DXXXXX, Either, Genome, Hepatitis A, Hepatitis D, Hepatitis E, Iin, MULTIPLE, Nucleotdies, Nucleotide, ONE, Q fever, Regions, THAN, TYPE, UAXXXX, UBXXXX, Vaccine, virus
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Rare / Neglected Diseases, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease
Attenuated Human Parainfluenza Virus (PIV) for Use as Live, Attenuated Vaccines and as Vector Vaccines
The identified technologies describe self-replicating infectious recombinant paramyxoviruses with one or more attenuating mutations, such as a separate variant polynucleotide encoding a P protein and a separate monocistronic polynucleotide encoding a V protein, or at least one temperature sensitive mutation and one non-temperature sensitive mutation....
Published: 10/28/2024   |   Inventor(s): Peter Collins, Sheila Nolan, Mario Skiadopoulos, Brian Murphy
Keywords(s): cDNA, CIS-ACTING, Complete, DC5BXX, DC5XXX, DCXXXX, Determination, DXXXXX, FOR..., FRAMES, Gene, Generate, Generation, Genomic, HPIV2, HPIV2., HPIV2/V94, Identification, MEASLES, Mumps, MUTATION, Novel, Nucleotide, Overlapping, P/V, Parainfluenza virus type 3, Parainfluenza virus type 3; Human parainfluenza virus type 3, Reading, recombinant, rHPIV2, Separated, sequence, Strain, UA1XXX, USEFUL, V94
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Rare / Neglected Diseases, Application > Vaccines, TherapeuticArea > Infectious Disease
Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4
The invention relates to a dengue virus tetravalent vaccine containing a common 30-nucleotide deletion (delta30) in the 3'-untranslated region (UTR) of the genome of dengue virus serotypes 1, 2, 3, and 4. The previously identified delta30 attenuating mutation, created in dengue virus type 4 (DEN4) by the removal of 30 nucleotides from the 3'-UTR, is...
Published: 10/28/2024   |   Inventor(s): Brian Murphy, Lewis Markoff, Barry Falgout, Kathryn Hanley, Joseph Blaney, Stephen Whitehead
Keywords(s): 3'-UTR, ANTIGENIC, chimeric, Chromosome 7, monosomy, DA4BXX, DA4XXX, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, Deletion, Deletion 7, DENGUE, Dengue (Flaviviridae), DXXXXX, Nucleotide, Tetravalent, UAXXXX, UBXXXX, Vaccine, Viruses
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Rare / Neglected Diseases, Application > Diagnostics, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Vaccines
Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus
West Nile virus (WNV) has recently emerged in the U.S. and is considered a significant emerging disease that has embedded itself over a considerable region of the U.S. WNV infections have been recorded in humans as well as in different animals. From 1999-2014, WNV killed 1,765 people in the U.S. and caused severe disease in more than 41,762 others....
Published: 10/28/2024   |   Inventor(s): Robert Chanock (Estate), Joseph Putnak, Brian Murphy, Joseph Blaney, Stephen Whitehead, Alexander Pletnev
Keywords(s): Chimeras, DC5BXX, DC5XXX, DCXXXX, DENGUE, Dengue (Flaviviridae), DXXXXX, Live, Nile, Vaccine, virus, VLXXXX, VOXXXX, WAXXXX, WBXXXX, West, WEST NILE VIRUS, WMXXXX, WNXXXX, XKXXXX, YCXXXX, YDXXXX
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Vaccines, Application > Consumer Products, Application > Diagnostics
Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses
Although flaviviruses cause a great deal of human suffering and economic loss, there is a shortage of effective vaccines. This invention relates to dengue virus mutations that may contribute to the development of improved dengue vaccines. Site directed and random mutagenesis techniques were used to introduce mutations into the dengue virus genome...
Published: 10/28/2024   |   Inventor(s): Joseph Blaney, Kathryn Hanley, Brian Murphy, Stephen Whitehead
Keywords(s): ATTENUATING, chimeric, DC5BXX, DC5XXX, DCXXXX, DENGUE, Dengue (Flaviviridae), Dengue Vaccine, Development, DXXXXX, Mutations, UAXXXX, UBXXXX, USEFUL, Viruses
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Rare / Neglected Diseases, TherapeuticArea > Infectious Disease
Murine Monoclonal Antibodies Effective To Treat Respiratory Syncytial Virus
Available for licensing through a Biological Materials License Agreement are the murine MAbs described in Beeler et al, "Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function," J Virol. 1989 Jul;63(7):2941-2950 (PubMed abs). The MAbs that are available for licensing are the following:...
Published: 10/28/2024   |   Inventor(s): Peter Collins, Kathleen Coelingh, Robert Chanock (Estate), Brian Murphy, Judith Beeler
Keywords(s): #s, 1107;, 1112;, 1121;, 1129;, 1142;, 1153;, 1175-40; 1113-44; 1105-1, 1200;, 1214;, 1269, Cell, DB4BXX, DBXXXX, DXXXXX, Hybridoma, Lines, monoclonal
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Materials Available, Application > Therapeutics, TherapeuticArea > Infectious Disease